{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T00:01:31Z","timestamp":1793232091535,"version":"4.5.0"},"reference-count":98,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2025,9,9]]},"abstract":"<jats:sec id=\"ab-jrv250016-1\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Osteoporosis is characterized by low bone mass, increased bone fragility, and increased susceptibility to fracture, which is associated with substantial morbidity, mortality, and economic costs. Worldwide, 1 in 3 women and 1 in 5 men older than 50 years of age experience osteoporotic fractures in their lifetime.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-jrv250016-2\">\n                    <jats:title>Observations<\/jats:title>\n                    <jats:p>Risk factors for osteoporosis include older age, female sex, prior fractures, prior falls, low body weight, history of hip fracture in a parent, glucocorticoid use, cigarette smoking, excess alcohol consumption, certain comorbidities (eg, inflammatory bowel disease, rheumatoid arthritis, and chronic liver and kidney disease), and low level of bone mineral density (BMD; measured by dual-energy x-ray absorptiometry). The fracture risk assessment algorithm combines these clinical risk factors and BMD measurement to estimate the 10-year absolute fracture risk for hip, spine, shoulder, and forearm fractures. For patients at high risk of fracture, such as those with a T score of \u20132.5 or less (equivalent to a bone mass that is \u22652.5 SDs below that of young adults) for BMD, history of vertebral or hip fracture, multiple fractures, or high 10-year absolute fracture risk (eg, \u226520%), antiresorptive agents (bisphosphonates or, if contraindicated, denosumab) are recommended to reduce vertebral fractures (risk difference, \u221252 [95% CI, \u221295 to \u221218 per 1000 person-years]) and hip fractures (risk difference, \u22126 [95% CI, \u221211 to \u22121 per 1000 person-years]). Anabolic medications (teriparatide, abaloparatide, and romosozumab) should be considered in very high-risk individuals (eg, recent vertebral fractures, hip fracture with a T score of \u2264\u22122.5 for BMD), followed by an antiresorptive agent. The use of fracture liaison services (comprehensive inpatient or outpatient management program for patients after a fracture) was shown to increase medication initiation and adherence by 38% compared with 17% for patients who did not receive fracture liaison services (risk difference, 20% [95% CI, 16% to 25%]) and these benefits may reduce the rates of subsequent fracture. Patients are recommended to follow appropriate intake of calcium (1000 to 1200 mg) and vitamin D (600 to 800 IU) guidelines and to pursue a regimen of muscle resistance exercises (eg, squats, push-ups) and balance exercises (eg, heel raises, standing on 1 foot).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-jrv250016-3\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>Osteoporosis is a common condition among older adults that leads to increased susceptibility to fracture, which is associated with substantial morbidity and mortality. Antiresorptive agents such as bisphosphonates or denosumab are recommended for patients at high fracture risk. Anabolic treatment with parathyroid hormone analogs (such as teriparatide and abaloparatide) and sclerostin inhibitors (such as romosozumab) can be considered for very high-risk individuals.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jama.2025.6003","type":"journal-article","created":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T11:00:31Z","timestamp":1751281231000},"page":"894","source":"Crossref","is-referenced-by-count":261,"title":["Osteoporosis"],"prefix":"10.1001","volume":"334","author":[{"given":"Suzanne N.","family":"Morin","sequence":"first","affiliation":[{"name":"Department of Medicine, McGill University, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William D.","family":"Leslie","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Manitoba, Winnipeg, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John T.","family":"Schousboe","sequence":"additional","affiliation":[{"name":"Park Nicollet Clinic and Health Partners Institute, Minneapolis, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"5","key":"jrv250016r2","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1007\/s00198-014-2655-z","article-title":"The clinical diagnosis of osteoporosis: a position statement from the National Bone Health Alliance Working Group.","volume":"25","author":"Siris","year":"2014","journal-title":"Osteoporos Int"},{"issue":"10","key":"jrv250016r3","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1007\/s00198-021-05900-y","article-title":"The clinician\u2019s guide to prevention and treatment of osteoporosis.","volume":"33","author":"LeBoff","year":"2022","journal-title":"Osteoporos Int"},{"issue":"4","key":"jrv250016r4","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1007\/s00198-019-04919-6","article-title":"Performance of predictive tools to identify individuals at risk of non-traumatic fracture: a systematic review, meta-analysis, and meta-regression.","volume":"30","author":"Beaudoin","year":"2019","journal-title":"Osteoporos Int"},{"key":"jrv250016r5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4158\/GL-2020-0524SUPPL","article-title":"American Association of Clinical Endocrinologists\/American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis\u20142020 update.","volume":"26","author":"Camacho","year":"2020","journal-title":"Endocr Pract"},{"issue":"1","key":"jrv250016r6","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s11657-022-01061-5","article-title":"UK clinical guideline for the prevention and treatment of osteoporosis.","volume":"17","author":"Gregson","year":"2022","journal-title":"Arch Osteoporos"},{"issue":"10","key":"jrv250016r7","doi-asserted-by":"publisher","first-page":"2791","DOI":"10.1007\/s00198-017-4153-6","article-title":"Costs of fragility hip fractures globally: a systematic review and meta-regression analysis.","volume":"28","author":"Williamson","year":"2017","journal-title":"Osteoporos Int"},{"issue":"4","key":"jrv250016r8","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/s41584-024-01094-9","article-title":"Evidence-based guideline for the management of osteoporosis in men.","volume":"20","author":"Fuggle","year":"2024","journal-title":"Nat Rev Rheumatol"},{"issue":"9","key":"jrv250016r9","doi-asserted-by":"publisher","first-page":"e580","DOI":"10.1016\/S2666-7568(21)00172-0","article-title":"Global, regional, and national burden of bone fractures in 204 countries and territories, 1990-2019: a systematic analysis from the Global Burden of Disease Study 2019.","volume":"2","author":"GBD 2019 Fracture Collaborators","year":"2021","journal-title":"Lancet Healthy Longev"},{"issue":"10","key":"jrv250016r10","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1007\/s00198-009-0920-3","article-title":"Excess mortality following hip fracture: a systematic epidemiological review.","volume":"20","author":"Abrahamsen","year":"2009","journal-title":"Osteoporos Int"},{"key":"jrv250016r11","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2022.116499","article-title":"Mechanisms of bone resorption.","volume":"163","author":"Everts","year":"2022","journal-title":"Bone"},{"issue":"3","key":"jrv250016r12","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1249\/JES.0000000000000225","article-title":"The central role of osteocytes in the four adaptive pathways of bone\u2019s mechanostat.","volume":"48","author":"Hughes","year":"2020","journal-title":"Exerc Sport Sci Rev"},{"key":"jrv250016r13","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1146\/annurev-bioeng-062117-121139","article-title":"Bone mechanical properties in healthy and diseased states.","volume":"20","author":"Morgan","year":"2018","journal-title":"Annu Rev Biomed Eng"},{"key":"jrv250016r14","doi-asserted-by":"publisher","first-page":"k3225","DOI":"10.1136\/bmj.k3225","article-title":"Assessment of the genetic and clinical determinants of fracture risk: genome wide association and mendelian randomisation study.","volume":"362","author":"Trajanoska","year":"2018","journal-title":"BMJ"},{"issue":"7","key":"jrv250016r15","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/j.eprac.2024.04.006","article-title":"Hormonal control of bone architecture throughout the lifespan: implications for fracture prediction and prevention.","volume":"30","author":"Grigoryan","year":"2024","journal-title":"Endocr Pract"},{"issue":"12","key":"jrv250016r16","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1002\/jbmr.3030","article-title":"Risk and prevention of fracture in patients with major medical illnesses: a mini-review.","volume":"31","author":"Cummings","year":"2016","journal-title":"J Bone Miner Res"},{"issue":"10","key":"jrv250016r17","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1002\/jbmr.2836","article-title":"Risk factors for hip fracture in older men: the osteoporotic fractures in men study (MrOS).","volume":"31","author":"Cauley","year":"2016","journal-title":"J Bone Miner Res"},{"issue":"12","key":"jrv250016r18","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1056\/NEJM199503233321202","article-title":"Risk factors for hip fracture in white women.","volume":"332","author":"Cummings","year":"1995","journal-title":"N Engl J Med"},{"issue":"2","key":"jrv250016r19","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s12020-018-1746-6","article-title":"Association between age at menopause and fracture risk: a systematic review and meta-analysis.","volume":"63","author":"Anagnostis","year":"2019","journal-title":"Endocrine"},{"issue":"5","key":"jrv250016r20","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/BF02390832","article-title":"A meta-analysis of the effects of cigarette smoking on bone mineral density.","volume":"68","author":"Ward","year":"2001","journal-title":"Calcif Tissue Int"},{"key":"jrv250016r21","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.drugalcdep.2019.01.025","article-title":"The effect of alcohol on osteoporosis: a systematic review and meta-analysis.","volume":"197","author":"Cheraghi","year":"2019","journal-title":"Drug Alcohol Depend"},{"issue":"20","key":"jrv250016r22","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1001\/jama.298.20.2381","article-title":"High-trauma fractures and low bone mineral density in older women and men.","volume":"298","author":"Mackey","year":"2007","journal-title":"JAMA"},{"issue":"1","key":"jrv250016r23","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.jclinepi.2010.07.007","article-title":"Which fractures are most attributable to osteoporosis?","volume":"64","author":"Warriner","year":"2011","journal-title":"J Clin Epidemiol"},{"issue":"39","key":"jrv250016r24","doi-asserted-by":"publisher","first-page":"E1333","DOI":"10.1503\/cmaj.221647","article-title":"Clinical practice guideline for management of osteoporosis and fracture prevention in Canada: 2023 update.","volume":"195","author":"Morin","year":"2023","journal-title":"CMAJ"},{"issue":"12","key":"jrv250016r25","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1007\/s00198-023-06870-z","article-title":"Previous fracture and subsequent fracture risk: a meta-analysis to update FRAX.","volume":"34","author":"Kanis","year":"2023","journal-title":"Osteoporos Int"},{"issue":"3","key":"jrv250016r26","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s00198-023-07012-1","article-title":"A meta-analysis of previous falls and subsequent fracture risk in cohort studies.","volume":"35","author":"Vandenput","year":"2024","journal-title":"Osteoporos Int"},{"issue":"6","key":"jrv250016r27","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1007\/BF01622200","article-title":"Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report.","volume":"4","author":"Kanis","year":"1994","journal-title":"Osteoporos Int"},{"issue":"7","key":"jrv250016r28","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1359\/JBMR.050304","article-title":"Predictive value of BMD for hip and other fractures.","volume":"20","author":"Johnell","year":"2005","journal-title":"J Bone Miner Res"},{"issue":"10","key":"jrv250016r29","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1001\/archinte.164.10.1108","article-title":"Bone mineral density thresholds for pharmacological intervention to prevent fractures.","volume":"164","author":"Siris","year":"2004","journal-title":"Arch Intern Med"},{"issue":"8","key":"jrv250016r30","doi-asserted-by":"publisher","first-page":"3514","DOI":"10.1210\/jc.2018-02614","article-title":"Two-thirds of all fractures are not attributable to osteoporosis and advancing age: implications for fracture prevention.","volume":"104","author":"Mai","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"jrv250016r31","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s40618-023-02219-9","article-title":"An overview of the use of the fracture risk assessment tool (FRAX) in osteoporosis.","volume":"47","author":"Schini","year":"2024","journal-title":"J Endocrinol Invest"},{"issue":"3","key":"jrv250016r32","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1002\/jbmr.3669","article-title":"The radiology of osteoporotic vertebral fractures revisited.","volume":"34","author":"Lentle","year":"2019","journal-title":"J Bone Miner Res"},{"issue":"4","key":"jrv250016r33","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1002\/jbmr.3222","article-title":"Comparative analysis of the radiology of osteoporotic vertebral fractures in women and men: cross-sectional and longitudinal observations from the Canadian Multicentre Osteoporosis Study (CaMos).","volume":"33","author":"Lentle","year":"2018","journal-title":"J Bone Miner Res"},{"issue":"6","key":"jrv250016r34","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1001\/jama.2024.27154","article-title":"Screening for osteoporosis to prevent fractures: US Preventive Services Task Force recommendation statement.","volume":"333","author":"Nicholson","year":"2025","journal-title":"JAMA"},{"issue":"12","key":"jrv250016r35","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1016\/j.clnu.2023.10.013","article-title":"The effect of overweight or obesity on osteoporosis: a systematic review and meta-analysis.","volume":"42","author":"Liu","year":"2023","journal-title":"Clin Nutr"},{"issue":"1","key":"jrv250016r36","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1001\/jama.2024.8481","article-title":"Interventions to prevent falls in community-dwelling older adults: US Preventive Services Task Force recommendation statement.","volume":"332","author":"Nicholson","year":"2024","journal-title":"JAMA"},{"issue":"9","key":"jrv250016r37","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/afac205","article-title":"World guidelines for falls prevention and management for older adults: a global initiative.","volume":"51","author":"Montero-Odasso","year":"2022","journal-title":"Age Ageing"},{"issue":"2","key":"jrv250016r38","doi-asserted-by":"publisher","DOI":"10.1093\/ptj\/pzaa221","article-title":"Progressive resistance training for improving health-related outcomes in people at risk of fracture: a systematic review and meta-analysis of randomized controlled trials.","volume":"101","author":"Ponzano","year":"2021","journal-title":"Phys Ther"},{"issue":"1","key":"jrv250016r39","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012424.pub2","article-title":"Exercise for preventing falls in older people living in the community.","volume":"1","author":"Sherrington","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"issue":"24","key":"jrv250016r41","doi-asserted-by":"publisher","first-page":"2466","DOI":"10.1001\/jama.2017.19344","article-title":"Association between calcium or vitamin D supplementation and fracture incidence in community-dwelling older adults: a systematic review and meta-analysis.","volume":"318","author":"Zhao","year":"2017","journal-title":"JAMA"},{"issue":"11","key":"jrv250016r42","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/S2213-8587(18)30265-1","article-title":"Effects of vitamin D supplementation on musculoskeletal health: a systematic review, meta-analysis, and trial sequential analysis.","volume":"6","author":"Bolland","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"jrv250016r43","doi-asserted-by":"publisher","DOI":"10.1016\/j.nut.2023.112151","article-title":"Supplementation of vitamin D isolated or calcium-associated with bone remodeling and fracture risk in postmenopausal women without osteoporosis: a systematic review of randomized clinical trials.","volume":"116","author":"Reis","year":"2023","journal-title":"Nutrition"},{"issue":"2","key":"jrv250016r44","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s00198-012-2224-2","article-title":"Health risks and benefits from calcium and vitamin D supplementation: Women\u2019s Health Initiative clinical trial and cohort study.","volume":"24","author":"Prentice","year":"2013","journal-title":"Osteoporos Int"},{"key":"jrv250016r45","doi-asserted-by":"publisher","first-page":"d2040","DOI":"10.1136\/bmj.d2040","article-title":"Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women\u2019s Health Initiative limited access dataset and meta-analysis.","volume":"342","author":"Bolland","year":"2011","journal-title":"BMJ"},{"issue":"8","key":"jrv250016r46","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1210\/clinem\/dgae290","article-title":"Vitamin D for the prevention of disease: an Endocrine Society clinical practice guideline.","volume":"109","author":"Demay","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"jrv250016r47","doi-asserted-by":"publisher","first-page":"182","DOI":"10.7326\/M22-0684","article-title":"Effectiveness and safety of treatments to prevent fractures in people with low bone mass or primary osteoporosis: a living systematic review and network meta-analysis for the American College of Physicians.","volume":"176","author":"Ayers","year":"2023","journal-title":"Ann Intern Med"},{"issue":"5","key":"jrv250016r48","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1210\/jc.2019-00192","article-title":"Efficacy of pharmacological therapies for the prevention of fractures in postmenopausal women: a network meta-analysis.","volume":"104","author":"Barrionuevo","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"jrv250016r49","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1093\/jbmr\/zjae068","article-title":"Pre-treatment bone mineral density and the benefit of pharmacologic treatment on fracture risk and BMD change: analysis from the FNIH-ASBMR SABRE project.","volume":"39","author":"Schini","year":"2024","journal-title":"J Bone Miner Res"},{"issue":"29","key":"jrv250016r50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta24290","article-title":"Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation.","volume":"24","author":"Davis","year":"2020","journal-title":"Health Technol Assess"},{"issue":"9","key":"jrv250016r51","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1007\/s40520-023-02478-9","article-title":"Efficacy of osteoporosis pharmacological treatments in men: a systematic review and meta-analysis.","volume":"35","author":"Beaudart","year":"2023","journal-title":"Aging Clin Exp Res"},{"issue":"78","key":"jrv250016r52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta20780","article-title":"A systematic review and economic evaluation of bisphosphonates for the prevention of fragility fractures.","volume":"20","author":"Davis","year":"2016","journal-title":"Health Technol Assess"},{"issue":"4","key":"jrv250016r53","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/jcph.2181","article-title":"Efficacy and safety of annual infusion of zoledronic acid and weekly oral alendronate in the treatment of primary osteoporosis: a meta-analysis.","volume":"63","author":"Wang","year":"2023","journal-title":"J Clin Pharmacol"},{"issue":"8","key":"jrv250016r54","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1359\/JBMR.040325","article-title":"Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.","volume":"19","author":"Chesnut","year":"2004","journal-title":"J Bone Miner Res"},{"issue":"10329","key":"jrv250016r55","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/S0140-6736(21)02646-5","article-title":"Drug therapy for osteoporosis in older adults.","volume":"399","author":"Reid","year":"2022","journal-title":"Lancet"},{"key":"jrv250016r56","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2021.116297","article-title":"Bisphosphonates and the risk of atypical femur fractures.","volume":"156","author":"Black","year":"2022","journal-title":"Bone"},{"issue":"8","key":"jrv250016r57","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis.","volume":"361","author":"Cummings","year":"2009","journal-title":"N Engl J Med"},{"issue":"8","key":"jrv250016r58","doi-asserted-by":"publisher","first-page":"3450","DOI":"10.1210\/jc.2019-00271","article-title":"Further nonvertebral fracture reduction beyond 3 years for up to 10 years of denosumab treatment.","volume":"104","author":"Ferrari","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"jrv250016r59","doi-asserted-by":"publisher","first-page":"37","DOI":"10.7326\/M19-0533","article-title":"Long-term drug therapy and drug discontinuations and holidays for osteoporosis fracture prevention: a systematic review.","volume":"171","author":"Fink","year":"2019","journal-title":"Ann Intern Med"},{"issue":"1","key":"jrv250016r60","doi-asserted-by":"publisher","first-page":"51","DOI":"10.7326\/M19-0961","article-title":"National Institutes of Health Pathways to Prevention Workshop: research gaps for long-term drug therapies for osteoporotic fracture prevention.","volume":"171","author":"Siu","year":"2019","journal-title":"Ann Intern Med"},{"issue":"6","key":"jrv250016r61","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1001\/jama.2023.28239","article-title":"Severe hypocalcemia with denosumab among older female dialysis-dependent patients.","volume":"331","author":"Bird","year":"2024","journal-title":"JAMA"},{"issue":"1","key":"jrv250016r62","doi-asserted-by":"publisher","first-page":"10892","DOI":"10.1038\/s41598-023-37944-x","article-title":"Atypical femur fracture associated with common anti-osteoporosis drugs in FDA adverse event reporting system.","volume":"13","author":"Xiao","year":"2023","journal-title":"Sci Rep"},{"issue":"6","key":"jrv250016r63","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1210\/jc.2018-01965","article-title":"Invasive oral procedures and events in postmenopausal women with osteoporosis treated with denosumab for up to 10 years.","volume":"104","author":"Watts","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"jrv250016r64","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1002\/jbmr.3337","article-title":"Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension.","volume":"33","author":"Cummings","year":"2018","journal-title":"J Bone Miner Res"},{"issue":"9","key":"jrv250016r65","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1002\/jbmr.4335","article-title":"Fractures after denosumab discontinuation: a retrospective study of 797 cases.","volume":"36","author":"Burckhardt","year":"2021","journal-title":"J Bone Miner Res"},{"key":"jrv250016r66","article-title":"Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS.","author":"Tsourdi","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"jrv250016r67","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1002\/jbmr.4705","article-title":"Multiple vertebral fractures after denosumab discontinuation: FREEDOM and FREEDOM extension trials additional post hoc analyses.","volume":"37","author":"Cosman","year":"2022","journal-title":"J Bone Miner Res"},{"issue":"2","key":"jrv250016r68","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa062462","article-title":"Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women.","volume":"355","author":"Barrett-Connor","year":"2006","journal-title":"N Engl J Med"},{"issue":"7","key":"jrv250016r69","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1001\/jama.282.7.637","article-title":"Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial.","volume":"282","author":"Ettinger","year":"1999","journal-title":"JAMA"},{"issue":"19","key":"jrv250016r70","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.","volume":"344","author":"Neer","year":"2001","journal-title":"N Engl J Med"},{"issue":"7","key":"jrv250016r71","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1001\/jama.2016.11136","article-title":"Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial.","volume":"316","author":"Miller","year":"2016","journal-title":"JAMA"},{"issue":"9","key":"jrv250016r72","doi-asserted-by":"publisher","DOI":"10.1002\/jbm4.10665","article-title":"Teriparatide and osteosarcoma risk: history, science, elimination of boxed warning, and other label updates.","volume":"6","author":"Krege","year":"2022","journal-title":"JBMR Plus"},{"issue":"8","key":"jrv250016r73","doi-asserted-by":"publisher","first-page":"2915","DOI":"10.1210\/jc.2008-2630","article-title":"Effects of teriparatide treatment and discontinuation in postmenopausal women and eugonadal men with osteoporosis.","volume":"94","author":"Leder","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"16","key":"jrv250016r74","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis.","volume":"375","author":"Cosman","year":"2016","journal-title":"N Engl J Med"},{"issue":"8","key":"jrv250016r75","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1002\/jbmr.3452","article-title":"Effects of 24 months of treatment with romosozumab followed by 12 months of denosumab or placebo in postmenopausal women with low bone mineral density: a randomized, double-blind, phase 2, parallel group study.","volume":"33","author":"McClung","year":"2018","journal-title":"J Bone Miner Res"},{"issue":"3","key":"jrv250016r76","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1002\/jbmr.3622","article-title":"One year of romosozumab followed by two years of denosumab maintains fracture risk reductions: results of the FRAME extension study.","volume":"34","author":"Lewiecki","year":"2019","journal-title":"J Bone Miner Res"},{"issue":"15","key":"jrv250016r77","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or alendronate for fracture prevention in women with osteoporosis.","volume":"377","author":"Saag","year":"2017","journal-title":"N Engl J Med"},{"issue":"5","key":"jrv250016r78","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1210\/jc.2019-00221","article-title":"Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society* clinical practice guideline.","volume":"104","author":"Eastell","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"jrv250016r79","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa048","article-title":"Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society guideline update.","volume":"105","author":"Shoback","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"24","key":"jrv250016r80","doi-asserted-by":"publisher","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","article-title":"Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial.","volume":"296","author":"Black","year":"2006","journal-title":"JAMA"},{"issue":"2","key":"jrv250016r81","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1002\/jbmr.1494","article-title":"The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT).","volume":"27","author":"Black","year":"2012","journal-title":"J Bone Miner Res"},{"issue":"7","key":"jrv250016r82","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1002\/jbmr.3420","article-title":"Bisphosphonate drug holiday and fracture risk: a population-based cohort study.","volume":"33","author":"Adams","year":"2018","journal-title":"J Bone Miner Res"},{"issue":"12","key":"jrv250016r83","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.25190","article-title":"Bisphosphonate treatment beyond 5 years and hip fracture risk in older women.","volume":"3","author":"Izano","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"5","key":"jrv250016r84","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1097\/MLR.0000000000001294","article-title":"Duration of bisphosphonate drug holidays and associated fracture risk.","volume":"58","author":"Curtis","year":"2020","journal-title":"Med Care"},{"issue":"2","key":"jrv250016r85","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1002\/jbmr.3051","article-title":"Treatment sequence matters: anabolic and antiresorptive therapy for osteoporosis.","volume":"32","author":"Cosman","year":"2017","journal-title":"J Bone Miner Res"},{"issue":"8","key":"jrv250016r86","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1007\/s00198-022-06386-y","article-title":"Effects of prior osteoporosis treatment on the treatment response of romosozumab followed by denosumab in patients with postmenopausal osteoporosis.","volume":"33","author":"Ebina","year":"2022","journal-title":"Osteoporos Int"},{"issue":"9999","key":"jrv250016r87","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(15)61120-5","article-title":"Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial.","volume":"386","author":"Leder","year":"2015","journal-title":"Lancet"},{"issue":"7","key":"jrv250016r88","doi-asserted-by":"publisher","DOI":"10.1002\/jbm4.10512","article-title":"Skeletal responses to romosozumab after 12 months of denosumab.","volume":"5","author":"McClung","year":"2021","journal-title":"JBMR Plus"},{"issue":"7","key":"jrv250016r89","doi-asserted-by":"publisher","first-page":"465","DOI":"10.7326\/M15-2937","article-title":"Change in bone mineral density is an indicator of treatment-related antifracture effect in routine clinical practice: a registry-based cohort study.","volume":"165","author":"Leslie","year":"2016","journal-title":"Ann Intern Med"},{"issue":"1","key":"jrv250016r90","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.18954","article-title":"Reassessment intervals for transition from low to high fracture risk among adults older than 50 years.","volume":"3","author":"Leslie","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"8","key":"jrv250016r91","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1002\/jbmr.2888","article-title":"Addressing the crisis in the treatment of osteoporosis: a path forward.","volume":"16","author":"Khosla","year":"2016","journal-title":"J Bone Miner Res"},{"key":"jrv250016r92","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.bone.2018.03.018","article-title":"Fracture liaison services improve outcomes of patients with osteoporosis-related fractures: a systematic literature review and meta-analysis.","volume":"111","author":"Wu","year":"2018","journal-title":"Bone"},{"issue":"6","key":"jrv250016r93","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1007\/s00198-023-06688-9","article-title":"International consensus on the non-pharmacological and non-surgical management of osteoporotic vertebral fractures.","volume":"34","author":"Ponzano","year":"2023","journal-title":"Osteoporos Int"},{"issue":"1","key":"jrv250016r94","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1007\/s11657-021-00919-4","article-title":"Use of an electronic medical record dashboard to identify gaps in osteoporosis care.","volume":"16","author":"Papaioannou","year":"2021","journal-title":"Arch Osteoporos"},{"issue":"6","key":"jrv250016r95","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1007\/s11914-019-00543-9","article-title":"Bone Health TeleECHO: a force multiplier to improve the care of skeletal diseases in underserved communities.","volume":"17","author":"Lewiecki","year":"2019","journal-title":"Curr Osteoporos Rep"},{"issue":"6","key":"jrv250016r96","doi-asserted-by":"publisher","DOI":"10.1002\/hsr2.849","article-title":"Current situation of shared decision making in osteoporosis: a comprehensive literature review of patient decision aids and decision drivers.","volume":"5","author":"Nogu\u00e9s","year":"2022","journal-title":"Health Sci Rep"},{"issue":"5","key":"jrv250016r97","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1210\/jc.2019-00193","article-title":"Women\u2019s values and preferences regarding osteoporosis treatments: a systematic review.","volume":"104","author":"Barrionuevo","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"jrv250016r98","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1007\/s00198-019-05248-4","article-title":"Patient engagement in clinical guidelines development: input from &gt;?1000 members of the Canadian Osteoporosis Patient Network.","volume":"31","author":"Morin","year":"2020","journal-title":"Osteoporos Int"},{"key":"jrv250016r40","volume-title":"Dietary Reference Intakes for Calcium and Vitamin D","author":"Ross","year":"2011"},{"key":"jrv250016r1","unstructured":"World Health Organization. Guidelines for preclinical evaluation and clinical trials in osteoporosis. Published in 1998. Accessed May 20, 2025. https:\/\/iris.who.int\/bitstream\/handle\/10665\/42088\/9241545224_eng.pdf"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2835762\/jama_morin_2025_rv_250016_1756415893.87594.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T15:00:55Z","timestamp":1757430055000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2835762"}},"subtitle":["A Review"],"short-title":[],"issued":{"date-parts":[[2025,9,9]]},"references-count":98,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,9,9]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2025.6003","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9,9]]}}}